Andrzej

Andrzej Czarnecki,
MD, PhD, DSc

Member, Audit Committee

Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd.

Andrzej Czarnecki is a physician and a scientist. He has a distinguished career spanning over many years in medicine, pharmacology, regulation and pharmacovigilance in regulatory authorities and industry, and as a consultant to public bodies e.g. WHO and EU Commission projects and governments of countries on different continents (Denmark, Slovenia, Germany, Kazakhstan, Ukraine, Kyrgyzstan and others).

Dr. Czarnecki has also been active at several universities as Professor of Pharmacoepidemiology and head of PV and Clinical Trials Departments, authoring over 120 research papers. He is a member of several professional societies an elected fellow of the Faculty of Pharmaceutical Medicine and the International Society of Pharmacoepidemiology.

Dr. Czarnecki joined DIA in 1992. He has been a member of Steering Committees: for International Development (1997-99) and of Europe (SCE: 1996-2004), first as a regulator and later as an industry representative. After stepping down from the SCE, Dr. Czarnecki was appointed Editor-in-Chief of DIA Forum by the DIA Board of Directors. He was chair of the DIA 2003 EuroMeeting, and a member of the programme and advisory committees for several subsequent DIA EuroMeetings (2001-2007), workshops, and training courses. In the 1990s Dr. Czarnecki led the DIA expansion into Central/Eastern Europe and championed numerous contacts with regulatory authorities. In recognition of his contributions, he received the DIA ‘Outstanding Services Award’ in 2004. In 2009, Dr. Czarnecki transformed DIA Forum into the Global Forum, which he continued to lead until being elected to the Board in 2013.

Our Leadership